DOI: https://dx.doi.org/10.18203/2320-1770.ijrcog20222324
Published: 2022-08-29

Successful outcome of pregnancy with chronic myeloid luekamia with preterm premature rupture of membranes

Aditi Pradeep Kaundinya, Pia Muriel Cardoso

Abstract


The concomitant occurrence of pregnancy and chronic myeloid luekamia (CML) is uncommon and hence its management often poses a dilemma due to limited data available for the same. There is also very sparse data available with respect to the use of imatinib in pregnancy (which is usually the mainstay in the management of CML with few case reports suggesting congenital anomalies in the fetus. We presented a case report of a known case of CML who was in the chronic phase on tablet imatinib 300 mg OD. She presented with preterm premature rupture of membranes (PPROM) at 28 weeks and was given conservative management for the same, she went into preterm labour at 32 weeks and delivered vaginally a healthy 1.8 kg male baby without any intrapartum or postpartum complications. Both mother and baby were in good health at six month follow up. We had to weigh carefully the risks of immune-compromised state of the patient versus the complications of preterm delivery and tread through the management of this particular case. Use of imatinib did not cause any obvious congenital malformations in the baby.


Keywords


Chronic myeloid leukaemia, Imatinib, Preterm premature rupture of membranes, Hydroxyurea

Full Text:

PDF

References


Vita VT, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. 7th ed. Philadelphia: Lippincott, Williams and Wilkins; 2001: 121.

Juárez S, Cuadrado PJM, Feliu J, González BM, Ordóñez A, Montero JM. Association of leukemia and pregnancy: clinical and obstetric aspects. Am J Clin Oncol. 1988;11(2):159-65.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.

Bazarbashi MS, Smith MR, Karanes C, Zielinski I, Bishop CR. Successful management of Ph chromosome chronic myelogenous leukemia with leukapheresis during pregnancy. Am J Hematol. 1991;38(3):235-7.

Celiloglu M, Altunyurt S, Undar B. Hydroxyurea treatment for chronic myeloid leukemia during pregnancy. Acta Obstet Gynecol Scand. 2000;79(9):803-4.

Mubarak AA, Kakil IR, Awidi A, Al-Homsi U, Fawzi Z, Kelta M, et al. Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-alpha in 1st trimester: report of 3 cases and review of the literature. Am J Hematol. 2002;69(2):115-8.

Ali R, Ozkalemkas F, Kimya Y, Koksal N, Ozkocaman V, Gulten T, et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet. 2009;280(2):169-75.

Apperley J. CML in pregnancy and childhood. Best Pract Res Clin Haematol. 2009;22(3):455-74.

Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006;24(7):1204-8.

Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, Rosti G, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111(12):5505-8.

Russell MA, Carpenter MW, Akhtar MS, Lagattuta TF, Egorin MJ. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol. 2007;27(4):241-3.

Madabhavi I, Sarkar M, Modi M, Kadakol N. Pregnancy Outcomes in Chronic Myeloid Leukemia: A Single Center Experience. J Glob Oncol. 2019;5:1-11.